Skip to main content

Sarepta Therapeutics, Inc.

SRPT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000873303

No open-market purchases or sales by Sarepta Therapeutics, Inc. insiders were filed in the last 90 days; 323 institutions reported holding it in 13F filings for Q2 2026, worth $1.94B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Sarepta Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Sarepta Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Sarepta Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Wong Ryan Ho-YanChief Financial Officer121,792Sep 8, 20265
Estepan Ian MichaelChief Operating Officer177,184Sep 8, 20267
Rothfuss CristinEVP, General Counsel115,519Sep 8, 20265
Rodino-Klapac LouisePresident, R&D and Tech Ops203,900Sep 8, 20266
Severino MichaelChief Executive Officer756,104Jul 29, 20261
Behrens M KathleenDirector214,357Jun 5, 20262
Connelly Deirdre PDirector22,100Jun 5, 20261
Wigzell Hans Lennart RudolfDirector42,098Jun 5, 20261
Barry RichardDirector2,983,542Jun 5, 20261
Nicaise ClaudeDirector48,407Jun 5, 20262
Boor Kathryn JeanDirector25,138Jun 5, 20261
Mayo StephenDirector18,640Jun 5, 20262
Chambers Michael AndrewDirector27,535Jun 5, 20262
Ingram Douglas SChief Executive Officer929,391Dec 9, 20251
Arif BilalChief Tech Ops Officer32,500Aug 6, 20250
Murray DallanChief Customer Officer38,202Mar 11, 20250
Brown Ryan EdwardEVP, General Counsel17,129Jun 25, 20240
Gray Mary AnnDirector12,356Mar 8, 20220
Ciambrone WilliamEVP22,099Mar 8, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 13, 2026 (view filing)Mar 121 dayMayo StephenDirectorSSale−7.24K$17.02−$123.2K−80.4%1.76K after
Dec 18, 2025 (view filing)Dec 162 daysEstepan Ian MichaelChief Operating OfficerSSale−13.2K$22.31−$294.2K−6.4%193.3K after
Mar 13, 2025 (view filing)Mar 121 dayNicaise ClaudeDirectorSSale−2.49K$99.64−$248.2K−8.2%27.8K after
Dec 16, 2024 (view filing)Dec 124 daysWigzell Hans Lennart RudolfDirectorSSale−10.5K$124.84−$1.31M−31.5%22.8K after
Dec 6, 2024 (view filing)Dec 51 dayBoor Kathryn JeanDirectorSSale−1.64K$125.55−$205.4K−21.8%5.88K after
Sep 3, 2024 (view filing)Aug 304 daysEstepan Ian MichaelChief Financial OfficerSSale−5.99K$137.36−$822.1K−15.0%33.9K after
Aug 20, 2024 (view filing)Aug 164 daysChambers Michael AndrewDirectorPPurchase+37.0K$133.80+$4.96M+15.0%284.0K after3 lots
Jun 25, 2024 (view filing)Jun 25Same dayBrown Ryan EdwardEVP, General CounselSSale−39.0K$161.61−$6.30M−69.5%17.1K after7 lots10b5-1
Jun 25, 2024 (view filing)Jun 24-251 dayArif BilalChief Tech Ops OfficerSSale−11.8K$163.13−$1.92M−40.4%17.4K after6 lots10b5-1
May 6, 2024 (view filing)May 24 daysMurray DallanChief Customer OfficerSSale−3.63K$140.00−$508.9K−16.7%18.1K after10b5-1
Mar 11, 2024 (view filing)Mar 83 daysWigzell Hans Lennart RudolfDirectorSSale−15.0K$123.25−$1.85M−39.6%22.8K after3 lots
Mar 11, 2024 (view filing)Mar 11Same dayBoor Kathryn JeanDirectorSSale−761$122.93−$93.5K−9.2%7.52K after
Mar 6, 2024 (view filing)Mar 51 dayMayo StephenDirectorSSale−3.13K$122.96−$385.5K−32.1%6.62K after
Mar 5, 2024 (view filing)Mar 14 daysBrown Ryan EdwardEVP, General CounselSSale−2.00K$125.34−$250.7K−5.9%31.8K after
Mar 5, 2024 (view filing)Mar 14 daysArif BilalChief Tech Ops OfficerSSale−2.00K$128.84−$257.7K−6.9%26.8K after2 lots
Mar 5, 2024 (view filing)Mar 14 daysEstepan Ian MichaelChief Financial OfficerSSale−1.20K$128.30−$154.0K−3.0%39.1K after
Nov 6, 2023 (view filing)Nov 33 daysBarry RichardDirectorPPurchase+50.0K$78.81+$3.94M+55.6%140.0K after2 lots
Nov 6, 2023 (view filing)Nov 33 daysIngram Douglas SPresident & CEOPPurchase+25.2K$79.36+$2.00M+6.9%390.3K after4 lots
Aug 15, 2023 (view filing)Aug 141 dayChambers Michael AndrewDirectorPPurchase+9.98K$109.47+$1.09M+4.2%247.0K after2 lots
Aug 14, 2023 (view filing)Aug 113 daysChambers Michael AndrewDirectorPPurchase+23.7K$108.05+$2.56M+11.1%237.0K after
Aug 11, 2023 (view filing)Aug 101 dayChambers Michael AndrewDirectorPPurchase+34.9K$106.15+$3.70M+19.5%213.3K after3 lots
Aug 8, 2023 (view filing)Aug 44 daysWigzell Hans Lennart RudolfDirectorSSale−15.0K$106.72−$1.60M−41.7%21.0K after
Nov 21, 2022 (view filing)Nov 174 daysMayo StephenDirectorSSale−858$109.92−$94.3K−11.8%6.39K after
Sep 15, 2022 (view filing)Sep 141 dayChambers Michael AndrewDirectorPPurchase+57.1K$104.43+$5.96M+111.8%108.2K after3 lots
Aug 22, 2022 (view filing)Aug 193 daysChambers Michael AndrewDirectorPPurchase+46.2K$108.28+$5.00M+940.7%51.1K after2 lots
Nov 29, 2021 (view filing)Nov 245 daysRodino-Klapac LouiseHead of R&D, CSOPPurchase+3.78K$79.33+$299.9K+6.1%65.7K after
Nov 17, 2021 (view filing)Nov 17Same dayIngram Douglas SPresident & CEOPPurchase+25.0K$79.94+$2.00M+7.4%365.1K after